End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18,116 ARS | +6.42% | +3.10% | +10.09% |
02:38pm | Bristol Myers: positive results in liver cancer | CF |
Jun. 03 | Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies | MT |
Sales 2024 * | 46.09B 41,295B | Sales 2025 * | 46.06B 41,267B | Capitalization | 84.67B 75,866B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -4,851B | Net income 2025 * | 10.22B 9,157B | EV / Sales 2024 * | 2.68 x |
Net Debt 2024 * | 39.03B 34,975B | Net Debt 2025 * | 31.68B 28,382B | EV / Sales 2025 * | 2.53 x |
P/E ratio 2024 * |
-15.9
x | P/E ratio 2025 * |
7.9
x | Employees | 34,100 |
Yield 2024 * |
5.76% | Yield 2025 * |
6.05% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +6.42% | ||
1 week | +3.10% | ||
Current month | +6.42% | ||
1 month | +10.13% | ||
3 months | -1.66% | ||
6 months | +20.19% | ||
Current year | +10.09% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 18,116 | +6.42% | 2,041 |
24-05-31 | 17,023 | +4.01% | 1,415 |
24-05-30 | 16,367 | +0.08% | 3,307 |
24-05-29 | 16,354 | -2.16% | 765 |
24-05-28 | 16,714 | -4.87% | 2,983 |
End-of-day quote Buenos Aires S.E., June 02, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.60% | 748B | |
+33.78% | 598B | |
-5.74% | 356B | |
+17.79% | 325B | |
+3.37% | 283B | |
+17.17% | 245B | |
+9.36% | 211B | |
-3.84% | 209B | |
+1.81% | 166B |
- Stock Market
- Equities
- BMY Stock
- BMY Stock